Filing Details

Accession Number:
0001209191-21-052078
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-17 19:35:36
Reporting Period:
2021-08-13
Accepted Time:
2021-08-17 19:35:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1283303 E Elizabeth Reed C/O Travere Therapeutics, Inc.
3611 Valley Centre Dr., Suite 300
San Diego CA 92130
Svp, Gc & Corporate Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-13 4,500 $0.00 38,955 No 4 A Direct
Common Stock Disposition 2021-08-17 1,407 $17.12 37,548 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.
  2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.